# EGFR-ADC (Becotatug Vedotin) Combined With PD-1 Inhibitor (Pucotenlimab) in Neoadjuvant Treatment of Advanced Penile Cancer

> **NCT07518979** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Jiyan Liu** · enrollment: 60 (estimated)

## Conditions studied

- Penile Cancer

## Interventions

- **DRUG:** Becotatug Vedotin
- **DRUG:** Pucotenlimab

## Key facts

- **NCT ID:** NCT07518979
- **Lead sponsor:** Jiyan Liu
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-01
- **Primary completion:** 2028-05-01
- **Final completion:** 2031-05-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-04-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07518979

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07518979, "EGFR-ADC (Becotatug Vedotin) Combined With PD-1 Inhibitor (Pucotenlimab) in Neoadjuvant Treatment of Advanced Penile Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07518979. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*